ArticleFrontiers in oncology2025
Tumour habitat-based radiomics analysis enhances the ability to predict prostate cancer aggressiveness with biparametric MRI-derived features.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Development and validation of an MRI radiomics-based model for predicting progression risk in prostate cancer after endocrine therapy.Translational andrology and urology · 2026Article
- Interpretable habitat radiomics model based on multi-sequence MRI for risk prediction of metachronous liver metastasis in rectal cancer: a multicenter study.Japanese journal of radiology · 2026Article
- Temporal-spatial evolution of tumor habitat analysis: a bibliometric study on research hotspots and trends in medical imaging (2014-2025).Translational cancer research · 2026Article
- Habitat imaging combined with multimodal analysis for preoperative risk stratification of papillary thyroid carcinoma.Insights into imaging · 2025Article
- Multiparametric-MRI habitat radiomics analysis for discriminating pathological types of brain metastases.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of this study was to develop three predictive models utilising clinical factors, radiomics features, and habitat features, to distinguish between nonclinically significant prostate cancer (csPCa) and clinically significant PCa (non-csPCa) on the basis of biparametric MRI (bp-MRI). Methods: A total of 175 patients were enrolled, including 134 individuals with csPCa and 41 with non-csPCa. The clinical model was developed using optimal predictive factors obtained from univariable logistic regression and modelled through a random forest approach. Image acquisition and segmentation were performed first in the creation of both the radiomics model and the habitat model. The K-means clustering algorithm was then used exclusively for habitat generation in the development of the habitat model. Finally, feature selection and model construction were performed for both models. Model comparison and diagnostic efficacy assessment were conducted through receiver operating characteristic curve analysis, decision curve analysis (DCA), and calibration curve analysis. Results: The habitat model outperformed both the radiomics model and the clinical model in distinguishing csPCa from non-csPCa patients. The AUC values of the habitat model in the training and test sets were 0.99 and 0.93, respectively. Furthermore, DCA and the calibration curves highlighted the superior clinical utility and greater predictive accuracy of the habitat model in comparison with the other two models. Conclusion: We developed a habitat-based radiomics model with a greater ability to distinguish between csPCa and non-csPCa on the basis of bp-MRI than a traditional radiomics model and clinical model. This introduces a novel approach for assessing the heterogeneity of PCa and offers urologists a quantitative, noninvasive method for preoperatively evaluating the aggressiveness of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.